L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding
about
PPARs and the cardiovascular systemNew insights into the role of fatty acids in the pathogenesis and resolution of inflammatory bowel diseaseRole of Peroxisome Proliferator-Activated Receptor γ in Ocular DiseasesThe amino acid residues asparagine 354 and isoleucine 372 of human farnesoid X receptor confer the receptor with high sensitivity to chenodeoxycholateScintillation proximity assay (SPA) technology to study biomolecular interactions.Convergence of nitric oxide and lipid signaling: anti-inflammatory nitro-fatty acids.Peroxisome proliferator-activated receptor delta (PPARdelta )-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling.Modulation of microglial innate immunity in Alzheimer's disease by activation of peroxisome proliferator-activated receptor gamma.A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivityBeta-mecaptoethanol suppresses inflammation and induces adipogenic differentiation in 3T3-F442A murine preadipocytes.Dual roles for lipolysis and oxidation in peroxisome proliferation-activator receptor responses to electronegative low density lipoproteinMethylsulfonylnitrobenzoates, a new class of irreversible inhibitors of the interaction of the thyroid hormone receptor and its obligate coactivators that functionally antagonizes thyroid hormone.Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipaseHistone deacetylase inhibitors stimulate mitochondrial HMG-CoA synthase gene expression via a promoter proximal Sp1 site.Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome.N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo.Drug-targeted inhibition of peroxisome proliferator-activated receptor-gamma enhances the chemopreventive effect of anti-estrogen therapyA Role for the PPARgamma in Cancer Therapy.Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders.Selective Modulators of PPAR-gamma Activity: Molecular Aspects Related to Obesity and Side-Effects.Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer.Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents.Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree of unsaturation.Functional interaction between peroxisome proliferator-activated receptors-alpha and Mef-2C on human carnitine palmitoyltransferase 1beta (CPT1beta) gene activation.Spectroscopic analyses of the binding kinetics of 15d-PGJ2 to the PPARgamma ligand-binding domain by multi-wavelength global fitting.Alpha,beta-unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor gamma.T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities.Control of human carnitine palmitoyltransferase II gene transcription by peroxisome proliferator-activated receptor through a partially conserved peroxisome proliferator-responsive element.Peroxisome proliferator-activated receptor-gamma-independent inhibition of macrophage activation by the non-thiazolidinedione agonist L-796,449. Comparison with the effects of 15-deoxy-delta(12,14)-prostaglandin J(2).Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity.
P2860
Q24642728-425E89F2-2853-4485-97E2-A45CD9EDF2C2Q26851490-2117D851-EBC3-4685-A7B3-E8FAFD1B134BQ27022548-96C013C8-DFB9-4ED8-A85F-A4BE2328C463Q28217144-7CF207D1-5B83-4167-805F-7D4663D477D6Q30157691-0B5B3B5D-F51B-4868-BEBE-03DEE5A6AE9BQ30374785-8479B5BE-A5BE-452D-8C48-23E7A752FF30Q31537639-6B19E224-BB61-4CA0-AFBD-301AFEB60771Q33575523-850415A6-589F-44BA-A98C-923BE53E6B3CQ34249161-C8ECA8CC-CDFA-4455-AB96-B81D50D246F3Q34387568-B2C87CBC-91CD-472E-9420-0CFC8EFFE96EQ34509915-72060D2D-DC6A-437D-9293-3B0E722E55CFQ34751984-E800B238-AF2D-41BB-8DC3-F7A92B03E7DDQ34808268-59915407-E850-4455-AA54-88D05E02843AQ34909281-C7A5F626-322A-4FC0-8FD8-3B9E3164D26CQ35207615-2A1B2E52-8A8C-40FF-8FBE-14B229CD6076Q35842216-5C1E71C6-90BE-4864-B14B-473015BC0641Q35987100-67DE59C8-30B1-422D-81D9-987089EFFACDQ36691611-48FFD6AB-427F-4022-84B8-C779BE2F9CADQ36724770-7CAE2F5A-A95A-4BAA-B59F-CA9B9C7F3FEBQ36772301-C49743E7-6C66-4F24-ADE5-4A9808804D16Q36795404-9C637962-1925-4CF7-99A2-39134CB28B77Q37724195-C266B4B3-39BF-47F9-8616-E99D3B3E327EQ39806088-28BD3A75-9116-4FF7-9366-72F9D668E505Q40068129-5CFF96C0-55B8-47E2-8268-45F5F363CC4AQ40360288-1A67B6A2-63E2-405E-A790-66198EA4347AQ40461294-BE7F3D8C-DB84-4357-B7FB-4187BB905353Q40747044-68447FD2-923E-4DDD-A430-29441C83E51BQ43002627-AAB599C6-A585-4C72-87E3-06BBCAFB8C62Q43662741-C9525E72-0DED-4EC4-9C48-5C793D5679F3Q44019883-3FD5EC0F-8274-4C8C-82FA-923E7CA1F56C
P2860
L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
L-764406 is a partial agonist ...... le of Cys313 in ligand binding
@ast
L-764406 is a partial agonist ...... le of Cys313 in ligand binding
@en
L-764406 is a partial agonist ...... le of Cys313 in ligand binding
@nl
type
label
L-764406 is a partial agonist ...... le of Cys313 in ligand binding
@ast
L-764406 is a partial agonist ...... le of Cys313 in ligand binding
@en
L-764406 is a partial agonist ...... le of Cys313 in ligand binding
@nl
prefLabel
L-764406 is a partial agonist ...... le of Cys313 in ligand binding
@ast
L-764406 is a partial agonist ...... le of Cys313 in ligand binding
@en
L-764406 is a partial agonist ...... le of Cys313 in ligand binding
@nl
P2093
P2860
P356
P1476
L-764406 is a partial agonist ...... le of Cys313 in ligand binding
@en
P2093
A Elbrecht
D E Moller
P2860
P304
P356
10.1074/JBC.274.12.7913
P407
P577
1999-03-19T00:00:00Z